The FDA’s push to reclassify naloxone as an OTC product appears tepid and plodding. At a time when the nation is enduring a severe public health emergency – with record numbers of (illicit) opioid overdose-related deaths – it’s crucial that naloxone become available OTC as soon as possible.
FDA’s Push To Reclassify The Opioid Reversal Agent Naloxone As An OTC Product Needs To Show More Urgency
